Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brensocatib in adults with cystic fibrosis
NCT05090904Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of brensocatib in cystic fibrosis (CF), sponsored by Insmed Incorporated. Primary endpoints: Maximum Plasma Concentration of Brensocatib on Day 1, Maximum Plasma Concentration of Brensocatib on Day 28 and 6 more. Started Nov 2021; status: completed.
02
Drugs
brensocatib
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05090904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05090904.